Hauger R L, Scheinin M, Siever L J, Linnoila M, Potter W Z
Veterans Administration Medical Center, La Jolla, Calif.
Clin Pharmacol Ther. 1988 Jan;43(1):32-8. doi: 10.1038/clpt.1988.8.
Responses to intravenous clonidine, a possible central noradrenergic probe, were examined in patients with depression before and after treatment with clorgiline, a selective monoamine oxidase type A inhibitor. Pulse rate, mean arterial blood pressure, plasma norepinephrine, 3-methoxy-4-hydroxyphenylglycol, and growth hormone were measured. Clorgiline treatment (2.5 to 10 mg/day) produced a variable reduction in the hypotensive response to clonidine but did not influence heart rate or plasma norepinephrine responses. Clorgiline markedly reduced the urinary output of norepinephrine and metabolites, indicating a reduced turnover of norepinephrine. None of the measured parameters corresponded with clinical effect. These data suggest that any clorgiline-induced alterations in alpha 2-receptor function as measured by responses to clonidine are modest and highly variable. Furthermore, since the variable and inconsistent changes in alpha 2-receptor function are dissociated from the massive changes in norepinephrine metabolism, regulation of presynaptic alpha 2-receptors appears unlikely to mediate the effects of clorgiline in patients with depression.
对静脉注射可乐定（一种可能的中枢去甲肾上腺素能探针）的反应，在接受氯吉兰（一种选择性A型单胺氧化酶抑制剂）治疗前后的抑郁症患者中进行了检查。测量了脉搏率、平均动脉血压、血浆去甲肾上腺素、3-甲氧基-4-羟基苯乙二醇和生长激素。氯吉兰治疗（2.5至10毫克/天）使对可乐定的降压反应产生了不同程度的降低，但不影响心率或血浆去甲肾上腺素反应。氯吉兰显著降低了去甲肾上腺素及其代谢产物的尿量，表明去甲肾上腺素的周转率降低。所测量的参数均与临床疗效无关。这些数据表明，通过对可乐定的反应所测量的任何氯吉兰诱导的α2受体功能改变都是适度的且高度可变的。此外，由于α2受体功能的可变且不一致的变化与去甲肾上腺素代谢的大量变化无关，突触前α2受体的调节似乎不太可能介导氯吉兰对抑郁症患者的作用。
